SUCCESSFUL SINGLE-DOSE PROPHYLAXIS OF STAPHYLOCOCCUS-AUREUS FOREIGN-BODY INFECTIONS IN GUINEA-PIGS BY FLEROXACIN

被引:19
作者
BOUCHENAKI, N [1 ]
VAUDAUX, PE [1 ]
HUGGLER, E [1 ]
WALDVOGEL, FA [1 ]
LEW, DP [1 ]
机构
[1] HOP CANTONAL UNIV,DEPT MED,DIV INFECT DIS,GENEVA,SWITZERLAND
关键词
D O I
10.1128/AAC.34.1.21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Single-dose administration of fleroxacin was evaluated as a means of preventing foreign body infection due to staphylococci. Tissue cages were implanted into guinea pigs and subsequently infected (100% rate) with 102 or more CFU of Staphylococcus aureus Wood 46. When a single dose of 30 mg of fleroxacin or vancomycin per kg of body weight was administered intraperitoneally, bactericidal levels of the antimicrobial agent were found in the tissue cage fluid after 3 h (when guinea pigs were inoculated with S. aureus) and during the next 24 h. Either fleroxacin or vancomycin successfully prevented experimental infection in all tissue cages challenged by 102 CFU of S. aureus Wood 46. When tissue cages were challenged with 104 CFU of S. aureus Wood 46, however, fleroxacin was more effective than vancomycin (P < 0.05) in reducing colony counts below the detection limit of 10 CFU/ml in the inflammatory fluid of all tissue cages during the initial 48 h. In contrast to their initially different actions, the effects of the antibiotics were similar after 7 days, mostly because bacterial regrowth occurred more frequently in the fleroxacin-treated than in the vancomycin-treated tissue cages. These data show that experimental infections of subcutaneous tissue cages are a useful model for studying the prophylaxis of foreign body infections with antimicrobial agents.
引用
收藏
页码:21 / 24
页数:4
相关论文
共 24 条
[11]   CLINICAL PHARMACOKINETICS AND TOLERANCE OF FLEROXACIN IN HEALTHY MALE-VOLUNTEERS [J].
NAKASHIMA, M ;
KANAMARU, M ;
UEMATSU, T ;
TAKIGUCHI, A ;
MIZUNO, A ;
ITAYA, T ;
KAWAHARA, F ;
OOIE, T ;
SAITO, S ;
UCHIDA, H ;
MASUZAWA, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :133-144
[12]   FLEROXACIN - INVITRO ACTIVITY WORLDWIDE AGAINST 20,807 CLINICAL ISOLATES AND COMPARISON TO CIPROFLOXACIN AND NORFLOXACIN [J].
PAGANONI, R ;
HERZOG, C ;
BRAUNSTEINER, A ;
HOHL, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :3-17
[13]  
PETERS G, 1987, 3RD ECCM S FOR BOD R, P16
[14]   INVITRO SUSCEPTIBILITY OF STAPHYLOCOCCI TO FLEROXACIN IN COMPARISON WITH 6 OTHER QUINOLONES [J].
POHLOD, DJ ;
SARAVOLATZ, LD ;
SOMERVILLE, MM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :35-41
[15]  
SALVATI EA, 1988, ORTHOPEDIC INFECTION, P133
[16]  
SANDE MA, 1987, AM J MED, V82, P63
[17]   PHARMACOKINETICS AND BODY-FLUID PENETRATION OF FLEROXACIN IN HEALTHY-VOLUNTEERS [J].
SORGEL, F ;
METZ, R ;
NABER, K ;
SEELMANN, R ;
MUTH, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :155-167
[18]  
TSHEFU K, 1983, REV INFECT DIS, V5, pS474
[19]  
VANDAUX P, 1984, J INFECT DIS, V150, P546
[20]   SINGLE AND MULTIPLE DOSE PHARMACOKINETICS OF FLEROXACIN [J].
WEIDEKAMM, E ;
PORTMANN, R ;
PARTOS, C ;
DELL, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :145-154